Clinical Trials
6 trialsNCT04673617 2026-04-03
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Phase 1/2 Completed
NCT03666000 2026-02-02
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
Phase 1 Recruiting
NCT05336409 2025-12-18
ELiPSE-1
Century Therapeutics, Inc.
Phase 1 Terminated
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT03778619 2020-07-28
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Phase 1/2 Unknown
NCT00100737 2006-02-06
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
Chiron Corporation
Phase 2 Terminated